Revvity Inc.
Moat Score — Revvity Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Revvity's newborn and prenatal screening tests are embedded in regulatory-approved public health programs, and its reagent and assay IP across life sciences and diagnostics provide real, if not dominant, protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Revvity is meaningfully smaller than giants like Thermo Fisher and Danaher, which can outspend it on R&D and procurement, leaving it without a clear structural cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Embedded, regulatory-linked testing programs give some pricing durability, but Revvity faces intense competition from larger, better-resourced rivals across most of its life sciences and diagnostics categories. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Revvity's instruments, reagents, and diagnostic tests do not become more valuable to one customer as more customers adopt them; there is no network dynamic at play. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once a hospital or pharma lab standardizes on Revvity's instruments and validated assay workflows, replacing the matched reagents and revalidating clinical or research protocols is costly and slow, creating strong recurring-revenue lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Niches like newborn screening are relatively small, specialized markets where an established, regulator-trusted incumbent captures most of the available economics, discouraging new entrants from the capital outlay required to compete. |